홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

디페록사민

Deferoxamine

HCID 2973
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
70-51-9
표준 SMILES
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
InChIKey
UBQYURCVBFRUQT-UHFFFAOYSA-N
분자식
C25H48N6O8
평균 분자량
560.7 g/mol
단동위원소 질량
560.3533625

개요

Desferrioxamine B is an acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N1-(5-aminopentyl)-N1-hydroxy-N4-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator. It has a role as a ferroptosis inhibitor, a siderophore, an iron chelator and a bacterial metabolite. It is a conjugate base of a desferrioxamine B(1+). It is a conjugate acid of a desferrioxamine B(3-).

이름 및 식별자

우선 이름
Deferoxamine
IUPAC
N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide
현지명
디페록사민
영어명
Deferoxamine
분자식
C25H48N6O8
분자량
560.69

이름 및 동의어

deferoxamine70-51-9Desferrioxamine BDESFERRIOXAMINEDeferrioxamineDeferoxamine BDeferrioxamine BDeferoxaminDeferoxaminumDesferinDFOMDesferan
이름 더 보기
디페록사민DESFEROXAMINEtaoneentaoneba33112ba-29837ba-33112
DesferexDesferralDesferrinN-Benzoylferrioxamine BDeferoxaminaDFOANSC-527604Ferrioxamine B, N-benzoyl-

데이터베이스 식별자

CAS
70-51-9
PubChem CID
2973
DTXSID
DTXSID7022887
ChEMBL
CHEMBL556
ChEBI
CHEBI:4356
UNII
J06Y7MXW4D
EC Number
200-738-5
Nikkaji
J10.199K

물성

구조 계산 물성보충 중

XLogP
-2.1
극성 표면적
206 Ų
수소 결합 공여자 수
6
수소 결합 수용자 수
9
회전 가능 결합 수
23
무거운 원자 수
39
형식 전하
0
복잡도
739

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LipidsFatty Acyls [FA] -> Fatty amides [FA08] -> N-acyl amines [FA0802]
LogP · 2건

-2.2

-1.52

Solubility9.90e-02 g/L
Human Drugs · 2건

Breast Feeding; Lactation; Chelating Agents; Iron Chelating Agents

Antidotes and other substances used in poisonings > Specific

Melting Point · 3건

MP: 138-140 °C /MONOHYDRATE/; 172-175 °C /HYDROCHLORIDE/; 148-149 °C /METHANESULFONATE/

MP: 180-182 °C /N-ACETYL DERIV/

138 - 140 °C

Physical DescriptionSolid
Stability/Shelf LifeRECONSTITUTED SOLN ARE STABLE FOR 2 WK @ ROOM TEMP /MESYLATE/
Collision Cross Section228.86 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (97.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 69 reports by companies from 3 notifications to the ECHA C&L Inventory.

유해성 정보

Regulatory InformationStatus: Active Update: 07-06-2016 https://echa.europa.eu/registration-dossier/-/registered-dossier/17782
Hazard Classes and CategoriesAcute Tox. 4 (97.1%)

독성 정보

InteractionsTHE CONCOMITANT ORAL ADMINISTRATION OF ASCORBIC ACID (0.5 TO 1 G TWICE DAILY) SEEMS TO IMPROVE THE CHELATING ACTION OF DEFEROXAMINE IN HEMOCHROMATOSIS, PARTICULARLY IF THERE IS A VITAMIN C DEFICIENCY.
Hepatotoxicity · 1건

In large clinical trials, elevations in serum aminotransferase levels were rare in patients receiving deferoxamine and instances of acute, clinically apparent liver injury were not reported. Patients with transfusion related iron overload often have concurrent chronic hepatitis B or C, and elevations of serum aminotransferase levels during chelation therapy may be due to natural fluctuations in the underlying chronic liver disease activity. Nevertheless, elevations in serum aminotransferase levels and “hepatic dysfunction” are listed as potential adverse events in product labels for deferoxamine. After an early report of hepatitis occurring in patient on hemodialysis receiving deferoxamine to reduce aluminum levels, there have been no further published instances of clinically apparent liver injury that have been convincingly linked to deferoxamine therapy.

Adverse Effects

화학 및 산업

약리 정보

ATC Code · 4건

V03AC01

V - Various

QV - Various

V03AC01

Protein BindingLess than 10% bound to serum proteins <i>in vitro</i>.
Pharmacodynamics · 1건

Deferoxamine, otherwise known as desferrioxamine or desferal, is a chelating agent used to remove excess iron or aluminum from the body. It acts by binding free iron or aluminum in the bloodstream and enhancing its elimination in the urine. By removing excess iron or aluminum, the agent reduces the damage done to various organs and tissues, such as the liver.

Mechanism of Action · 3건

Deferoxamine works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming ferrioxamine, a stable complex which is eliminated via the kidneys. 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent (ferric) iron. Deferoxamine works in treating aluminum toxicity by binding to tissue-bound aluminum to form aluminoxamine, a stable, water-soluble complex. The formation of aluminoxamine increases blood concentrations of aluminum, resulting in an increased concentration gradient between the blood and dialysate, boosting the removal of aluminum during dialysis. 100 mg of deferoxamine is capable of binding approximately 4.1 mg of aluminum.

DEFEROXAMINE HAS...REMARKABLY HIGH AFFINITY FOR FERRIC IRON... IT...COMPETES FOR IRON OF FERRITIN & HEMOSIDERIN, BUT IT REMOVES ONLY SMALL AMOUNT OF IRON OF TRANSFERRIN. ... GIVEN ORALLY, DEFEROXAMINE BINDS IRON IN LUMEN OF BOWEL & RENDERS THE METAL NONABSORBABLE.

IT READILY COMPLEXES WITH FERRIC ION TO FORM FERRIOXAMINE, COLORED, STABLE, WATER-SOL CHELATE; IT ALSO HAS LIMITED AFFINITY FOR FERROUS ION. /MESYLATE/

Biological Half-LifeBiphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.
Metabolism/Metabolites · 2건

Deferoxamine is mainly metabolised in the plasma and hepatic metabolism is minimal. A number of metabolites have been isolated but not characterised. Some metabolites of deferoxamine, most notably the product of oxidative deamination, also chelate iron, and thus the antidotal effect of the drug appears unaffected by hepatic metabolism.

관련 반응

16건
반응 기록 만들기
HRID 24973 반응식
HRID 24973반응물로
HRID 24974 반응식
HRID 24974반응물로
HRID 24975 반응식
HRID 24975반응물로
HRID 979002 반응식
HRID 979002반응물로
HRID 1061480 반응식
HRID 1061480반응물로
HRID 1376572 반응식
HRID 1376572생성물로반응물로
HRID 1376573 반응식
HRID 1376573생성물로반응물로
HRID 1376574 반응식
HRID 1376574생성물로반응물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
Other Experimental Properties · 4건

CRYSTALS FROM DIL ALC /MONOHYDRATE/

CRYSTALS FROM SLIGHTLY ACIDIC METHANOL /HYDROCHLORIDE/

CRYSTALS FROM DIL ALC /METHANESULFONATE/

CRYSTALS FROM N-PROPANOL /N-ACETYL DERIV/

물리화학적 성질

녹는점
139 °C · 139°C
끓는 점
627.9 °C · 627.9°C (rough estimate)
밀도
1.2216 · 1.2216 (rough estimate)
굴절률
1.554 · 1.5540 (estimate)
저장 조건
-20 °C · -20°C
물리적 상태
Solid
산도 계수 (pKa)
9.08 · 9.08±0.50(Predicted)
색상
White to off-white
주요 응용
제약
InChIKey
UBQYURCVBFRUQT-UHFFFAOYSA-N
SMILES
C(=O)(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C
EPA
Deferoxamine (70-51-9)
· 1건

Chronic deferoxamine therapy can lead to sensorineural hearing loss and retinopathy. Though the mechanism of ocular injury is not well understood, it appears to partially occur due to damage to the retinal pigment epithelium, which can lead to decreased visual acuity, visual field defects, and color vision defects. Hearing and vision loss can be reversible if the patient discontinues the drug early in the course. Growth retardation can also occur in children receiving deferoxamine treatment, and clinicians should monitor patients for appropriate growth velocity over time.

Toxicity SummaryPatients tolerate deferoxamine well, and there is no specific antidote for the medication. The precautions and dose reductions are described elsewhere in this paper.
Human Toxicity Excerpts · 4건

PAIN & INDURATION MAY OCCUR @ SITE OF IM INJECTION. OTHER UNTOWARD EFFECTS INCL ERYTHEMA, FLUSHING, DIARRHEA, BLURRING OF VISION, ABDOMINAL DISCOMFORT, MUSCULAR SPASMS IN LEGS, ITCHING, TACHYCARDIA, & FEVER. IN LONG TERM THERAPY, VARIOUS ALLERGIC REACTIONS, INCL ANAPHYLAXIS, HAVE BEEN REPORTED. /MESYLATE/

REACTIONS HAVE INCLUDED HYPOTENSION, PROBABLY DUE TO HISTAMINE RELEASE (ESP DURING IV ADMIN), SKIN RASHES, & GI IRRITATION. OCCASIONAL CASES OF CATARACT FORMATION IN MAN HAVE BEEN REPORTED...

A WOMAN WITH BETA-THALASSAEMIA INTERMEDIA, AND IRON OVERLOAD FOLLOWING MANY YEAR'S THE COURSE OF THIS TREATMENT SHE DEVELOPED TINNITUS, WHICH WAS CONSIDERED TO BE A RARE COMPLICATION OF THE USE OF THIS CHELATING AGENT.

DESFERRIOXAMINE WAS GIVEN INTRAVENOUSLY, AT HIGHER DOSES THAN PREVIOUSLY REPORTED, TO COUNTER THE EFFECTS OF TRANSFUSION-INDUCED IRON OVERLOAD IN FOUR PATIENTS WITH BETA THALASSAEMIA MAJOR. IN TWO OF THEM RETINAL ABNORMALITIES DEVELOPED, PRESENTING WITH NIGHT BLINDNESS AND FIELD DEFECTS, WHICH IMPROVED ON WITHDRAWAL OF THE DRUG.

Drug Induced Liver Injury · 6건

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

deferoxamine

Desferal®

Chelating agents

Not Applicable

no-DILI-concern

Non-Human Toxicity Excerpts · 5건

DOGS TOLERATE SINGLE IV DOSES UP TO 100 MG/KG WITH SIGNS SUGGESTING TRANSIENT HYPOTENSION.

...IT HAS PRODUCED OPACITIES IN CRYSTALLINE LENS IN DOGS, CATS, & RATS WHEN GIVEN BY DAILY SC INJECTION FOR LONG PERIODS @ DOSAGES SO LARGE THAT THEY PRODUCE SEVERE GASTROENTERITIS.

INJECTION OF 28.5% SOLN SUBCONJUNCTIVALLY HAS CAUSED SLIGHT CHEMOSIS & HYPEREMIA. ... INJECTION OF 50 MG SUBCONJUNCTIVALLY WAS TOLERATED BY EYES OF MONKEYS...

...50 MG INJECTED SUBCONJUNCTIVALLY IN RABBITS EVERY 1-3 DAYS FOR SEVERAL MO WAS TOLERATED...BUT 200 MG SUBCONJUNCTIVALLY IN RABBITS CAUSED REDN IN RESPONSE OF PUPIL TO LIGHT, CONGESTION OF UVEA, & EXUDATIVE DETACHMENT OF CHOROID & RETINA...

INTRAVITREAL INJECTIONS OF 5 MG DEFEROXAMINE IN RABBITS PROVED VERY TOXIC, CAUSING WIDESPREAD HEMORRHAGIC NECROSIS, PARTICULARLY AFFECTING RODS & CONES OF RETINA & EXTINGUISHING ELECTRORETINOGRAM.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

wgk
WGK 3
독성
LD50 oral in mouse: 1340mg/kg
스토리지 클래스
11 - Combustible Solids
유해 물질 데이터
70-51-9(Hazardous Substances Data)

DEFEROXAMINE IS METABOLIZED PRINCIPALLY BY PLASMA ENZYMES, ALTHOUGH THE PATHWAYS HAVE NOT YET BEEN DEFINED.

FDA Pharmacological Classification · 5건

J06Y7MXW4D

DEFEROXAMINE

Mechanisms of Action [MoA] - Iron Chelating Activity

Established Pharmacologic Class [EPC] - Iron Chelator

Deferoxamine is an Iron Chelator. The mechanism of action of deferoxamine is as an Iron Chelating Activity.

MeSH Pharmacological ClassificationLow-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994)
Absorption, Distribution and Excretion · 3건

Deferoxamine is rapidly absorbed after intramuscular or subcutaneous administration, but only poorly absorbed from the gastrointestinal tract in the presence of intact mucosa.

Deferoxamine mesylate is metabolized principally by plasma enzymes, but the pathways have not yet been defined. Some is also excreted in the feces via the bile.

THE DRUG IS...READILY EXCRETED IN URINE.

Cellular LocationsCytoplasm

용도 및 제조

Uses · 2건

MEDICATION

Use (kg; approx.) in Germany (2009): >100

Methods of ManufacturingNATURAL PRODUCT FORMING IRON COMPLEXES, ISOLATED FROM STREPTOMYCES PILOSUS, ETTLINGER ET AL, ISOLATION: BICKEL ET AL, HELV CHIM ACTA 43, 2118 (1960). PREPN FROM FERRIOXAMINE B & STRUCTURE: BICKEL ET AL, HELV CHIM ACTA 43, 2129 (1960).
Formulations/Preparations · 2건

STERILE DEFEROXAMINE MESYLATE, USP (DESFERAL MESYLATE), IS AVAILABLE IN AMPULES CONTAINING 500 MG OF THE DRUG. /MESYLATE/

DESFERAL (CIBA). INJECTION: LYOPHILIZED POWDER (FOR SOLN) 500 MG.

General Manufacturing Information · 1건

THE IRON-CHELATING AGENT DESFERROXAMINE INHIBITED BOTH THE BASELINE AND IRON-STIMULATED AUTOXIDATION OF DOPAMINE OR NOREPINEPHRINE. DESFERROXAMINE APPEARS TO BE A USEFUL TOOL THAT MAY BE ADDED TO SOLUTIONS CONTAINING CATECHOLAMINES TO PREVENT THEIR DEGRADATION.

응용 분야 · 2건

개요Deferoxamine was introduced in the 1960s for chelation of iron. It is synthesized by removing a central iron molecule from ferrioxamine B, a compound obtained from the microorganism Streptomyces pilosus. Deferoxamine binds to iron from ferritin and forms ferrioxamine, a very stable and water-soluble chelate with a characteristic reddish color.

용도Deferoxamine is used for the treatment of both acute iron intoxication and chronic iron overload due to transfusiondependent anemias. It has also been used in trials for malaria treatment and for aluminum chelation in hemodialysis patients. Studies of a rat model of intracerebral hemorrhage have noted that deferoxamine treatment reduced oxidative stress from iron release, indicating a possible role in preventing damage associated with hemorrhagic strokes.

상·하류 제품 정보

상류 원료

디사이클로헥실카르보디이미디나트륨 사이아노브로민하이드라이드(나트륨 시아노브롬하이드리드)O-Benzylhydroxylamine hydrochloride숙신산무수물Palladium hydroxide무수초산Aluminium-nickel6-디메틸아미노퓨린4-[(5-{[(benzyloxy)carbonyl]amino}pentyl)(hydroxy)amino]-4-oxobutanoic acidButanoic acid, 4-[(4-cyanobutyl)(phenylmethoxy)amino]-4-oxo-benzyl N-[5-(N-hydroxy-3-{[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]carbamoyl}propanamido)pentyl]carbamateButanediamide, N'-[5-[[4-[[5-[acetyl(phenylmethoxy)amino]pentyl]amino]-1,4-dioxobutyl](phenylmethoxy)amino]pentyl]-N-(4-cyanobutyl)-N-(phenylmethoxy)- (9CI)(5-아미노펜틸)(페닐메톡시)카르밤산tert-부틸에스테르benzyl 5-(3,6-dioxomorpholino)pentylcarbamate벤질(5-(하이드록시아미노)펜틸)카바메이트